Copyright
©2010 Baishideng.
World J Gastroenterol. May 28, 2010; 16(20): 2484-2495
Published online May 28, 2010. doi: 10.3748/wjg.v16.i20.2484
Published online May 28, 2010. doi: 10.3748/wjg.v16.i20.2484
Table 1 Details of patients’ data
Case No. | Sex | Age (yr) | Type of disease | Anal lesion | Disease duration | Previous segmental resection | Initial onset or relapse | Hospitalization | |||||||
Fistula | Tag | On admission | Main medication | Duration of SVD (d) | On discharge | ||||||||||
CDAI | CRP (mg/dL) | CDAI | CRP (mg/dL) | Morphology | |||||||||||
1 | F | 52 | C | - | - | < 1 mo | - | I | 161 | 0.6 | Sulfasalazine | 58 | 25 | 0.9 | Active (CS) |
2 | M | 22 | C | + | + | 4 yr and 3 mo | + | R | 264 | 3.1 | Infliximab | 55 | 62 | 0 | NT |
3 | F | 21 | EC | + | - | 5 yr and 8 mo | - | R | 133 | 6.3 | Infliximab | 48 | 38 | 0 | NT |
4 | M | 22 | EC | + | - | 5 yr and 3 mo | - | R | 679 | 5.9 | Infliximab | 82 | 72 | 0.1 | Remission (CS) |
5 | M | 23 | EC | + | - | < 2 mo | - | I | 235 | 1.5 | Infliximab | 55 | 98 | 0.1 | Near remission (CS) |
6 | M | 28 | C | - | - | 2 mo | - | I | 88 | 2.5 | Infliximab | 68 | 59 | 0.5 | Near remission (CS) |
7 | F | 77 | C | - | - | 1 yr and 10 mo | - | R | 233 | 13.8 | Infliximab | 49 | 39 | 0 | Remission (CS and BE) |
8 | M | 30 | C | + | - | 6 mo | - | I | 281 | 4.6 | Infliximab | 50 | 39 | 0.1 | Remission (CS) |
9 | M | 55 | C | + | + | 8 mo | - | I | 172 | 1.0 | Infliximab | 46 | 67 | 0.5 | Remission (CS and BE) |
10 | M | 19 | EC | + | - | 4 mo | - | I | 147 | 0.8 | Infliximab | 43 | 40 | 0 | Remission (CS and BE) |
11 | F | 21 | EC | - | + | 3 mo | - | I | 335 | 6.0 | Infliximab | 49 | 47 | 0.3 | Improved still active (CS and BE) |
12 | F | 50 | E | - | - | 1 mo | - | I | 488 | 5.1 | Infliximab | 43 | 53 | 0 | Remission (CS) |
13 | M | 28 | C | - | - | 3 mo | - | I | 52 | 0.6 | Infliximab | 50 | 2 | 0 | Remission (CS) |
14 | M | 19 | EC | + | + | 2 yr and 1 mo | - | I | 193 | 0.8 | Infliximab | 43 | 35 | 0 | Near remission (CS and BE) |
15 | M | 29 | C | + | - | 1 yr and 4 mo | - | I | 126 | 0.2 | Infliximab | 43 | 8 | 0 | Improved still active (CS) |
16 | M | 30 | C | + | - | 1 yr and 1 mo | - | I | 211 | 11.8 | Infliximab | 47 | 28 | 0.8 | Near remission (CS and BE) |
17 | F | 21 | EC | - | + | 6 yr and 2 mo | - | R | 544 | 3.7 | Infliximab | 46 | 64 | 0.3 | Improved still active (BE) |
18 | F | 45 | EC | - | - | 13 yr | + | R, PO 21st d | 143 | 0.2 | Metronidazole | 19 | 105 | 0.1 | NT |
19 | M | 21 | EC | + | + | 2 yr | - | I, PO 13th d | 217 | 1.1 | Metronidazole | 18 | 166 | 0.1 | NT |
20 | M | 34 | EC | - | - | 17 yr | - | R, PO 12th d | 146 | 0 | Metronidazole | 24 | 108 | 0.1 | NT |
21 | M | 25 | C | - | + | 13 yr | - | R, PO 17th d | 372 | 7.1 | Metronidazole | 21 | 149 | 0 | NT |
22 | F | 23 | EC | - | - | 8 yr | - | R, PO 25th d | 151 | 8.0 | Metronidazole | 83 | 141 | 0.8 | NT |
Table 2 Nutritional data and hemoglobin during hospitalization
Case No. | Dietary pattern beforehospitalization | Hospitalization | |||||||||
On admission | On discharge | ||||||||||
BMI (kg/m2) | Albmin(g/dL) | Chol(mg/dL) | ChE(IU/mL) | Hemoglobin(g/dL) | BMI (kg/m2) | Albmin(g/dL) | Chol(mg/dL) | ChE(IU/mL) | Hemoglobin(g/dL) | ||
1 | Pro-Japanese | 21.1 | 4.7 | 155 | 4929 | 14.8 | 20.5 | 4.1 | 145 | 4959 | 13.0 |
2 | Standard | 17.2 | 3.8 | 140 | 4059 | 14.0 | 17.1 | 4.5 | 145 | 4170 | 15.5 |
3 | Japanese | 17.2 | 3.7 | 102 | 2003 | 8.3 | 19.2 | 4.0 | 152 | 4117 | 11.1 |
4 | Pro-Japanese | 18.5 | 2.8 | 100 | 789 | 8.6 | 17.9 | 3.0 | 116 | 1876 | 12.7 |
5 | Pro-western | 17.7 | 4.8 | 132 | 5592 | 15.8 | 17.0 | 4.2 | 135 | 5057 | 14.4 |
6 | Pro-western | 21.3 | 3.0 | 122 | 2876 | 10.8 | 20.7 | 4.4 | 192 | 4321 | 10.8 |
7 | Pro-Japanese | 17.2 | 2.1 | 95 | 1549 | 7.5 | 16.8 | 3.2 | 177 | 2633 | 11.6 |
8 | Pro-western | 19.2 | 3.2 | 128 | 3441 | 12.6 | 18.3 | 4.2 | 114 | 4911 | 14.3 |
9 | Japanese | 19.7 | 3.9 | 190 | 5094 | 13.0 | 18.2 | 4.1 | 221 | 4602 | 14.1 |
10 | Pro-western | 17.6 | 4.0 | 147 | 4505 | 13.5 | 17.6 | 4.5 | 154 | 4725 | 13.7 |
11 | Standard | 19.8 | 3.7 | 147 | 4081 | 9.5 | 18.4 | 3.9 | 125 | 4837 | 10.3 |
12 | Standard | 24.1 | 4.4 | 149 | 5156 | 11.0 | 21.4 | 4.3 | 158 | 6626 | 10.7 |
13 | Standard | 24.4 | 4.6 | 151 | 4599 | 16.2 | 22.5 | 4.4 | 143 | 4376 | 15.1 |
14 | Pro-western | 19.0 | 4.7 | 167 | 5722 | 15.0 | 18.8 | 4.4 | 138 | 4861 | 16.0 |
15 | Pro-western | 24.1 | 4.6 | 188 | 5755 | 15.4 | 22.4 | 4.5 | 137 | 5643 | 15.8 |
16 | Pro-western | 22.5 | 3.7 | 138 | 3757 | 12.3 | 21.4 | 4.4 | 116 | 4304 | 14.3 |
17 | Standard | 18.8 | 3.8 | 187 | 2700 | 10.6 | 18.1 | 4.1 | 209 | 2798 | 11.8 |
18 | Pro-Japanese | 21.6 | 4.1 | 126 | 7943 | 10.7 | 21.9 | 3.9 | 129 | 9098 | 10.8 |
19 | Pro-western | 20.1 | 4.1 | 150 | 3320 | 11.0 | 20.1 | 4.2 | 152 | 3426 | 11.8 |
20 | Polymeric diet | 18.1 | 3.9 | 100 | 3512 | 11.0 | 17.9 | 4.1 | 130 | 3757 | 13.4 |
21 | Standard | 15.6 | 3.5 | 116 | 3387 | 10.2 | 15.6 | 4.0 | 138 | 3870 | 11.9 |
22 | Pro-Japanese | 16.5 | 3.2 | 58 | 2320 | 9.9 | 16.0 | 2.9 | 78 | 3355 | 9.8 |
Table 3 Lifestyle and dietary habits
Every day | 3-5 times/wk | 1-2 times/wk | Rare | None | |
Smoking (No. of cigarettes/d) | 20 ≤ | 6-19 | 1-5 | Rare | P |
Regular exercise | R | R | R | P | |
Alcohol | P | ||||
Eating between meals | P | R | R | ||
Type of diet (D) | Semi-vegetarian (R) | Japanese | Pro-Japanese | Standard/mixed | Pro-western (P) |
Food | |||||
Rice | P | ||||
Miso soup | P | ||||
Pulses | R | P | |||
Vegetables | R | P | |||
Udon/soba (Japanese noodles) | P | ||||
Ramen (Chinese noodles) | P | R | |||
Bread (D) | P | R | |||
Tea, coffee | Canned coffee (P) | R | |||
(Sugar in tea or coffee) (D) | Large amount (P) | Average amount | Small amount | Rare | None (R) |
Juice | P | R | R | ||
Cola/soda | P | ||||
Beef | P | R | |||
Pork/chicken (D) | P | R | |||
Minced or processed meat | P | R | |||
Fish | P | ||||
Cheese/butter/margarine | P | R | |||
Sweets (D) | P | R | R | ||
Ice cream/milk shake | P | ||||
Yoghurt (plain) | R | P | |||
Green tea (D) | R | P | |||
Potatoes/starches (D) | R | P | |||
Fruits (D) | R | P |
Table 4 Content of semi-vegetarian diet (2000 kcal/d)
SVD | DRI | |
Energy | ||
Protein (%) | 16.1 ± 0.5 | < 20 |
Fat (%) | 18.6 ± 1.4 | 20-30 |
Carbohydrate (%) | 66.1 ± 1.6 | 50-70 |
Content | ||
Protein (g) | 80.3 ± 3.0 | M 60, F 50 |
Fat (g) | 41.4 ± 3.6 | |
Carbohydrate (g) | 330.2 ± 11.4 | |
Dietary fiber (g) | 32.4 ± 2.1 | M 20, F 17 |
Soluble dietary fiber (g) | 6.8 ± 0.7 | |
Insoluble dietary fiber (g) | 23.3 ± 1.6 | |
Calcium (mg) | 873.7 ± 65.2 | M 600-650, F 600 |
Phosphorus (mg) | 1882.7 ± 101.8 | M 1050, F 900 |
Iron (mg) | 19.3 ± 1.3 | M 7.5, F 10.5 |
Sodium (mg) | 4492.9 ± 342.1 | 600 |
Kalium (mg) | 4281.7 ± 250.6 | M 2000, F 1600 |
Vitamin A (μgRE) | 1416.6 ± 360.9 | M 750, F 600 |
Vitamin B1 (mg) | 2.0 ± 0.2 | M 1.4, F 1.1 |
Vitamin B2 (mg) | 1.3 ± 0.2 | M 1.6, F 1.2 |
Niacin (mg) | 26.6 ± 3.1 | M 15, F 12 |
Vitamin C (mg) | 133.1 ± 23.4 | 100 |
Vitamin D (μg) | 3.2 ± 1.0 | 5 |
Vitamin E (mg) | 12.3 ± 1.9 | M 9, F 8 |
Cholesterol (mg) | 285.9 ± 72.1 | M < 700, F < 600 |
NaCl (g) | 10.9 ± 0.8 | M < 10, F < 8 |
Polyunsaturated fatty acid (g) | 13.9 ± 1.9 | |
Monounsaturated fatty acid (g) | 9.3 ± 0.9 | |
Saturated fatty acid (g) | 7.1 ± 0.9 | |
P:S ratio | 2.0 ± 0.2 |
Table 5 Follow-up study
Case No. | Main medication | Dietary pattern | Days of remission | Reason for termination | On final attendance | |||||||||
Month 3 | Year 1 | Year 2 | On relapse | CDAI | CRP (mg/dL) | BMI (kg/m2) | Alb (g/dL) | Chol (mg/dL) | ChE (IU/mL) | Hemoglobin (g/dL) | ||||
1 | SSZ for 1 yr | SVD | SVD | SVD | 730 | Completion | 0 | 0.1 | 23.1 | 4.5 | 235 | 5684 | 14.4 | |
2 | Mesalamine | SVD | Omni | Omni | 301 | Relapse | 193 | 8.2 | 17.5 | 3.8 | 151 | 3262 | 13.8 | |
3 | Mesalamine | SVD | Omni | Omni | 367 | Relapse | 167 | 11.3 | 21.1 | 3.5 | 133 | 3551 | 10.0 | |
4 | Mesalamine | SVD | SVD | SVD | 730 | Completion | 128 | 5.0 | 18.7 | 2.8 | 114 | 1113 | 9.3 | |
5 | SSZ for 1 yr | SVD | SVD | 523 | Moving | 39 | 0 | 19.4 | 4.5 | 194 | 5509 | 15.0 | ||
6 | Mesalamine | Omni | Omni | 191 | Relapse | 192 | 5.7 | 21.7 | 3.9 | 134 | 3052 | 7.9 | ||
7 | None | SVD | SVD | 442 | INFX for RA | 61 | 2.0 | 19.6 | 4.0 | 158 | 5068 | 10.9 | ||
8 | Mesalamine | SVD | SVD | SVD | 635 | Relapse | 174 | 7.6 | 19.1 | 3.1 | 88 | 2678 | 11.3 | |
9 | Mesalamine | Omni | Omni | Omni | 730 | Completion | 48 | 0.2 | 19.8 | 4.3 | 171 | 5461 | 15.2 | |
10 | Mesalamine | SVD | SVD | SVD | 730 | Completion | 18 | 0.1 | 18.2 | 5.1 | 181 | 4659 | 16.3 | |
11 | Mesalamine | SVD | SVD | SVD | 730 | Completion | 11 | 0 | 19.7 | 4.7 | 147 | 5215 | 13.9 | |
12 | Mesalamine | SVD | SVD | SVD | 730 | Completion | 45 | 0 | 20.2 | 4.7 | 163 | 6268 | 11.3 | |
13 | Mesalamine | SVD | SVD | SVD | 730 | Completion | 0 | 0 | 22.8 | 4.6 | 171 | 4770 | 15.6 | |
14 | Mesalamine | SVD | SVD | 666 | Ongoing | 27 | 0.1 | 19.3 | 4.7 | 188 | 6084 | 15.1 | ||
15 | Mesalamine | SVD | Omni | 560 | Ongoing | 0 | 0 | 22.6 | 4.8 | 185 | 5671 | 16.8 | ||
16 | Mesalamine | SVD | SVD | 440 | Ongoing | 19 | 1.9 | 21.8 | 4.4 | 141 | 5146 | 14.2 | ||
17 | Mesalamine | SVD | SVD | 397 | Ongoing | 32 | 2.0 | 22.5 | 3.6 | 216 | 2683 | 11.1 | ||
18 | Mesalamine | SVD | SVD | SVD | 730 | Completion | 25 | 0.4 | 22.6 | 3.7 | 151 | 10222 | 11.1 | |
19 | Mesalamine | SVD | SVD | SVD | 730 | Completion | 62 | 0 | 20.1 | 4.7 | 139 | 4391 | 13.3 | |
20 | None | SVD | SVD | SVD | 730 | Completion | 37 | 0.7 | 18.2 | 4.5 | 156 | 5655 | 13.2 | |
21 | SSZ | SVD | SVD | SVD | 730 | Completion | 16 | 0.1 | 19.0 | 4.9 | 205 | 6424 | 14.4 | |
22 | Mesalamine | SVD | Omni | Omni | 630 | Relapse | 118 | 5.1 | 22.1 | 3.5 | 84 | 3596 | 10.1 |
Table 6 Maintenance therapy in Crohn's disease following induction of remission or response
Induction therapy | Maintenance therapy | ||||
Subjects | Regimen | Regimen | Duration | ||
1 yr | 2 yr | ||||
Candy et al[55], 1995 | CDAI > 200 | PS (diminishing dose) + AZA 12 wk | AZA 2.5 mg/kg | Remission rate 42% (14/33) | |
Placebo | 7% (2/30) | ||||
Hanauer et al[56], 2002 | CDAI ≥ 220 | Gr (1) and Gr (2) | Gr (1) INFX 5 mg/kg every 8 wk | Remission rate 25% (28/113) | |
Responder to a single infusion of infliximab | INFX 5 mg/kg at weeks 0, 2, 6 | Gr (2) INFX 10 mg/kg every 8 wk | 33% (37/112) | ||
Gr (3) INFX 5 mg/kg then placebo infusion at weeks 2, 6 | Gr (3) placebo infusion every 8 wk | 11% (12/110) | |||
Sandborn et al[58], 2005 | Mild to moderate CD | Budesonide 6 mg or 3 mg | Budesonide 6 mg or 3 mg | Relapse rate 60%-70% | |
Placebo | (In all 3 groups) | ||||
Takagi et al[39], 2006 | Active CD | TPN (25 cases), TEN (22 cases), | ED (half) + a free diet (half) | Relapse rate 26.9% (7/26) | |
PS (1 case), INFX (3 cases) | A free diet | 64.0% (16/25) | |||
Regueiro et al[59], 2009 | CD patients who had surgery | Ileocolonic resection | INFX 5 mg/kg at weeks 0, 2, 6 | Remission rate 80% (8/10) | |
then every 8 wk | |||||
Placebo | 58% (7/13) | ||||
Present study | Active CD | INFX 5 mg/kg at weeks 0, 2, 6 (16 cases), intestinal resection (5 cases), SSZ (1 case) | Semi-vegetarian diet | Remission rate 100% (16/16) | 92% |
Omnivorous diet | 67% (4/6) | 25% |
Table 7 Conventional and current diet in IBD at Nakadori General Hospital
Conventional | Current | |
Diet | Low-residue diet | Semi-lactoovovegetarian diet |
Menu | Common for UC and CD | SVD for UC (staple: white rice) |
SVD for RUC (staple: white rice 70%, brown rice 30%) | ||
SVD for CD (staple: brown rice) | ||
Refrainment | Fiber-rich diet | Minced or processed meat, bread, fast foods, sweets, cola/soda, juices |
Dairy products | Refrainment | Egg, milk: no refrainment |
Refrain from cheese/butter/margarine | ||
Calories | 2000 kcal/d | About 30 kcal/kg standard body weight/d |
Dietary analysis | Absent | Food-frequency questionnaire |
Dietary guidance | Absent | Guidance by doctor and registered dietitian |
- Citation: Chiba M, Abe T, Tsuda H, Sugawara T, Tsuda S, Tozawa H, Fujiwara K, Imai H. Lifestyle-related disease in Crohn’s disease: Relapse prevention by a semi-vegetarian diet. World J Gastroenterol 2010; 16(20): 2484-2495
- URL: https://www.wjgnet.com/1007-9327/full/v16/i20/2484.htm
- DOI: https://dx.doi.org/10.3748/wjg.v16.i20.2484